Earnings call transcript: H&H Group reports robust growth in H2 2025

H&H Group reported full-year revenue of RMB 14.3bn (+10.3% YoY) and net profit up 22.7% with an adjusted EBITDA margin of 14.3%; the stock rose ~3.16% post-results. Management maintained a HKD 0.35/share dividend (30% payout), reduced debt by ~HKD 603m, ended 2025 with HKD 1.7bn cash and lowered leverage to ~3.045x; guidance shows EPS of $0.17 (FY2026) and $0.22 (FY2027) with revenue forecasts of $2.28bn and $2.36bn. Key risks include tariff impacts, supply‑chain disruption, regulatory changes in China and FX exposure, but management plans continued innovation, localization and deleveraging to support growth.

Analysis

H&H’s playbook — premiumization + channel mix shift into short-video platforms — creates a predictable two-phase P&L dynamic: near-term margin pressure from higher S&D and channel acquisition cost, followed by durability gains as scale and SKU rationalization convert traffic into higher-ASP repeat buyers. Expect the biggest operational lever to be supply-chain localization for PNC: once manufacturing shifts in-country (end-2026 target), gross margins should re-expand materially, but the transition window (next 6–12 months) is a potential earnings trough due to one-off setup and SKU re-certification costs.

Second-order winners are omnichannel retailers that can capture spillover from influencer-driven education without ceding margin to platform promo cycles; membership warehouse and select big-box retailers get disproportionately high conversion from premium health SKUs. Conversely, pure-play programmatic ad vendors and export-focused suppliers to China face pressure as brands prioritize direct-to-consumer ecosystems and local manufacturing — a structural reallocation of marketing and supply-chain spend over 12–36 months.

Key binary risks: (1) adverse rulings from the Australian tax authority or further tariff moves could force a material one-off cash outflow inside 12–24 months; (2) regulatory tightening of cross-border infant formula or pet supplement channels in China could flip market-share gains to a volatile 2–4 quarter hangover. Monitor inventory turns and regional ASPs as lead indicators — a deceleration in inventory turnover or rapid ASP discounting on Douyin would presage margin compression ahead of guidance revisions.

Key Decisions for Investors

• Long COST vs short WMT pair (6–12 months): overweight COST by 1.5x notional vs underweight WMT to capture membership-led conversion of premium health supplements into higher basket spend; target asymmetric upside 15–30% vs downside ~10% if macro slows (stop-loss: 8% haircut on COST leg).
• Long CHWY (6–12 months): buy shares or 9–12 month calls to capture accelerating pet supplement penetration and Zesty Paws distribution gains across e‑commerce and retail; risk/reward ~2:1 (target +25–35%, downside 12–15% from margin squeeze or stock multiple compression).
• Event-driven long SMCI (12 months, options): buy 12-month calls to play incremental AI/big-data capex from consumer goods players modernizing merchandising and supply-chain analytics; payoff skewed >3x if enterprise AI budgets hold, with downside equal to premium paid if AI cycle slows.
• Hedge / protection: buy 6–9 month puts on AMZN or a small-market-cap adtech proxy if Douyin/TikTok ad monetization and direct-brand channels accelerate — protects against a reallocation of digital ad spend away from programmatic and Amazon-centric funnels (pay 1–2% notional for ~10–15% downside protection).